The Effect of Hydralazine on Early Stage Alzheimer’s Disease: A Randomized Clinical Trial (EHSAN)
Journal Title: The 2nd Annual Meeting of International Center for Neuroscience Research - Year 2021, Vol 2, Issue 1
Abstract
Objective: Hydralazine significantly delays the progression of Alzheimer's disease compared with placebo. Study population and sampling method: The study population in this study are all patients who have a possible diagnosis of Alzheimer's disease based on NINCDS-ADRDA. This randomized clinical trial will be conducted on 424 randomly selected patients over the age of 50 using random permuted blocks (each block consists of four participants) who are diagnosed with mild to moderate AD, after exclusion of dementia patients with etiologies other than AD (i.e. vascular related). This is a parallel double armed randomized clinical trials with allocation ratio of 1-1 to the intervention and placebo arms. The two arms of the study are Hydralazine 75mg (25mg three times per day) or Hydralazine placebo. Participants, outcome evaluators, researchers, and questioners will be blinded to the study arms. Screening phase: In the screening phase, the Mini-Mental State Examination (MMSE) and Palliativ Performance Scale (PPS) are taken, and then blood pressure, ECG, and blood tests are taken from the patient. Study phase: In this phase, the patient will answer the Alzheimer's Disease Assessment Scale (ADAS-cog) with the help of psychologist and the caregiver will complete the Neuropsychiatric Inventory (NPI), the Caregiver Activity Survey (CAS), and the Lawton Instrumental Activities of Daily Living (IADL) Scale with another psychologist. Follow up: All randomized patients are followed up in the clinic every 3 months (average follow-up 1 year).
Authors and Affiliations
Masoud Mirzaei and Nastaran Ahmadi*
Keywords
Related Articles
- EP ID EP701759
- DOI -
- Views 87
- Downloads 0
Intranasal Administration of Epidermal Neural Crest Stem Cells Improved Impairments in the Rat Model of Ischemic Stroke
Stem cell-based therapy has received considerable attention as a potential candidate in the domain of ischemic stroke treatment. However, employing appropriate type of stem cells and effective delivery of these cells to...
An Overview of the Importance of Biomarkers and Challenges in Neuroscience drug Discovery
Biomarkers are widely used for disease diagnosis, treatment response monitoring, and the development of novel therapeutics. However, advances in establishing biomarkers for disorders of the nervous system have been dis...
Combined Royal Jelly and Environmental Enrichment Effects Against Chronic Stress-Induced Memory Impairment
Background & Aims: Exposure to chronic stress has been demonstrated to impair memory processing. The effective therapeutic ways such as enriched environment (EE) and royal jelly (RJ) have been indicated in previous stu...
Decoding Selective Attention and Cognitive Control Processing through the Stroop Interference Effect: An Event-Related Electroencephalography-Derived Study
Background: The process of cognitive control and resultant selective attention constructs the very shared root of a continuum of neurocognitive functions. Efficient inhibition of the task-irrelevant information and unwa...
Roflumilast Attenuates Neuroinflammation and Cognitive Impairment in Intracerbroventricular-Streptozotocin Induced Rat Model of Sporadic Alzheimer’s Disease through Modulation of cAMP/BDNF Signaling Pathway
Sporadic Alzheimer’s disease (SAD) is the most complex and multifactorial neurodegenerative disease characterized by progressive cognitive deficits and memory loss. Phosphodiesterase (PDE) inhibitors prevent the breakd...